influenza%20(pediatric)
INFLUENZA (PEDIATRIC)
Influenza may present as a mild respiratory illness similar to the common cold or it may present without characteristic signs and symptoms.
The main type of influenza virus are types A, B & C virus. Types A&B are the main causes of influenza outbreaks.
Patient may appear flushed and have pain on eye movement. Non-exudative pharyngitis, scattered rales or rhonchi may be present.

Prevention

  • Vaccines are the primary preventive measure against influenza
  • Vaccine used should comply with current World Health Organization (WHO) recommendations
    • Annual seasonal influenza vaccination is recommended for all pediatric patients ≥6 months of age
      • Highly recommended for pediatric patients at increased risk for complications (ie patients with asthma, cardiac disease, immunosuppression, neurodevelopmental disorders)

Influenza Vaccine (Injections)

Composition:

  • WHO has a global influenza surveillance program
    • The collaborating centers provide early warning system for emerging strains of influenza that have epidemic potential
    • This system is necessary to create effective vaccines that contain the current circulating strains
  • Valency & composition depends upon the number & type of strains covered by the vaccine:
    • Trivalent vaccines: contains 2 type A strains & 1 type B strain of influenza
    • Quadrivalent vaccines: contains 2 type A strains & 2 type B strains of influenza
    • Recommended vaccine composition is issued yearly by WHO in March for vaccines used in the southern hemisphere & in October for vaccines in the northern hemisphere
  • Equatorial regions will need to use epidemiological considerations to determine which recommendations (March or October) are appropriate for their region

Inactivated Influenza Vaccine [Intramuscular (IM) or Deep Subcutaneous (SC)]

  • Uses vaccine composition issued by WHO in March (southern hemisphere) & in October (northern hemisphere)
  • Various types of inactivated influenza vaccine have been formulated to increase immunogenicity: split-virion,whole-virion, surface-antigen/adjuvant containing vaccines (eg aluminum, monophosphoryl lipid, virosome)
  • If the vaccine used contains the predominant circulating influenza strains, the vaccine can be 70-90% effective in preventing illness in healthy adults
  • Patients with concurrent medical conditions may have a reduced rate of severe respiratory illness & death (up to 50%)
    • Main benefit of vaccination in these patients is the prevention of severe consequences of infection rather than preventing uncomplicated illness
  • Vaccines that conform to international standards of purity & potency are usually free from systemic side effects

Live, Attenuated Influenza Vaccine (Intranasal)

  • Approved in some countries for the following uses:
    • Option for vaccination of healthy persons aged 2-49 years old
    • May be used in healthy individuals aged 2-49 years in close contact with high-risk groups except those in close contact with immunocompromised patients, or children aged 2-4 years diagnosed with asthma or with wheezing episode within the past 12 months
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
09 Apr 2016
Among adolescents who have only received diphtheria, tetanus toxoids, acellular pertussis (DTaP) vaccines in childhood, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine provides moderate protection against pertussis during the first year and then wanes rapidly thereafter.
26 Jul 2007
Despite the prevalence of corticosteroid use in infants with bronchiolitis, data on its efficacy is insufficient. In this study, oral dexamethasone was compared with placebo in the treatment of bronchiolitis.